These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7700026)

  • 1. Pretreatment with divided doses of steroids strongly decreases side effects of OKT3.
    Bemelman FJ; Buysmann S; Surachno J; Wilmink JM; Schellekens PT; ten Berge IJ
    Kidney Int; 1994 Dec; 46(6):1674-9. PubMed ID: 7700026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increase of sTNF receptor levels in acute renal allograft rejection after treatment with OKT3.
    Bemelman FJ; Jansen J; van der Poll T; van Deventer SJ; ten Berge RJ
    Nephrol Dial Transplant; 1994; 9(12):1786-90. PubMed ID: 7708265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants.
    Flechner SM; Goldfarb DA; Fairchild R; Modlin CS; Fisher R; Mastroianni B; Boparai N; O'Malley KJ; Cook DJ; Novick AC
    Transplantation; 2000 Jun; 69(11):2374-81. PubMed ID: 10868643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased dermal expression of ICAM-1 and VCAM-1 after administration of OKT3 in man.
    Buysmann S; van Diepen FN; Surachno S; Pals ST; ten Berge RJ
    Clin Nephrol; 1996 Aug; 46(2):84-91. PubMed ID: 8869784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation.
    Norman DJ; Kahana L; Stuart FP; Thistlethwaite JR; Shield CF; Monaco A; Dehlinger J; Wu SC; Van Horn A; Haverty TP
    Transplantation; 1993 Jan; 55(1):44-50. PubMed ID: 8420063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of indomethacin on the febrile response following OKT3 therapy.
    First MR; Schroeder TJ; Hariharan S; Alexander JW; Weiskittel P
    Transplantation; 1992 Jan; 53(1):91-4. PubMed ID: 1733091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy.
    Wissing KM; Morelon E; Legendre C; De Pauw L; LeBeaut A; Grint P; Maniscalki M; Ickx B; Vereerstraeten P; Chatenoud L; Kreis H; Goldman M; Abramowicz D
    Transplantation; 1997 Oct; 64(7):999-1006. PubMed ID: 9381549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3--a randomized, double-blind placebo-controlled study.
    Vincenti F; Danovitch GM; Neylan JF; Steiner RW; Everson MP; Gaston RS
    Transplantation; 1996 Feb; 61(4):573-7. PubMed ID: 8610383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity of OKT3 increases with dosage: a controlled study in renal transplant recipients.
    Parlevliet KJ; Bemelman FJ; Yong SL; Hack CE; Surachno J; Wilmink JM; ten Berge IJ; Schellekens PT
    Transpl Int; 1995; 8(2):141-6. PubMed ID: 7766296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial.
    Waid TH; Lucas BA; Thompson JS; McKeown JW; Brown S; Kryscio R; Skeeters LJ
    Transplantation; 1997 Jul; 64(2):274-81. PubMed ID: 9256187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective analysis of the effect of indomethacin on adverse reactions to orthoclone OKT3 in the therapy of acute renal allograft rejection.
    Gaughan WJ; Francos BB; Dunn SR; Francos GC; Burke JF
    Am J Kidney Dis; 1994 Sep; 24(3):486-90. PubMed ID: 8079974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OKT3 first-dose reaction: association with T cell subsets and cytokine release.
    Gaston RS; Deierhoi MH; Patterson T; Prasthofer E; Julian BA; Barber WH; Laskow DA; Diethelm AG; Curtis JJ
    Kidney Int; 1991 Jan; 39(1):141-8. PubMed ID: 1900552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids.
    Chatenoud L; Ferran C; Legendre C; Thouard I; Merite S; Reuter A; Gevaert Y; Kreis H; Franchimont P; Bach JF
    Transplantation; 1990 Apr; 49(4):697-702. PubMed ID: 2109379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reduction of TNF-alpha release and clinical effects of the first injection of OKT3].
    Meulders Q; Dallel T; Peraldi MN; Kanfer A; Sraer JD; Rondeau E
    Presse Med; 1992 Dec; 21(41):2024-6. PubMed ID: 1294974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome.
    Eason JD; Pascual M; Wee S; Farrell M; Phelan J; Boskovic S; Blosch C; Mohler KM; Cosimi AB
    Transplantation; 1996 Jan; 61(2):224-8. PubMed ID: 8600628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of OKT3 therapy for acute rejection in isolated lung transplantation.
    Shennib H; Massard G; Reynaud M; Noirclerc M
    J Heart Lung Transplant; 1994; 13(3):514-9. PubMed ID: 8061029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.
    Woodle ES; Xu D; Zivin RA; Auger J; Charette J; O'Laughlin R; Peace D; Jollife LK; Haverty T; Bluestone JA; Thistlethwaite JR
    Transplantation; 1999 Sep; 68(5):608-16. PubMed ID: 10507477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Half dose of OKT3 is efficient in treatment of steroid-resistant renal allograft rejection.
    Midtvedt K; Tafjord AB; Hartmann A; Eide TC; Holdaas H; Nordal KP; Draganov B; Sødal G; Leivestad T; Fauchald P
    Transplantation; 1996 Jul; 62(1):38-42. PubMed ID: 8693541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OKT3-induced nephrotoxicity is associated with release of group II secretory phospholipase A2.
    Wever PC; Roest RW; Wolbink-Kamp AM; Wolbink GJ; Weening JJ; Hack CE; ten Berge JM
    Eur J Clin Invest; 1996 Oct; 26(10):873-8. PubMed ID: 8911860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.